Read by QxMD icon Read


shared collection
6 papers 0 to 25 followers
Keunchil Park, Chong-Jen Yu, Sang-We Kim, Meng-Chih Lin, Virote Sriuranpong, Chun-Ming Tsai, Jong-Seok Lee, Jin-Hyoung Kang, K C Allen Chan, Pablo Perez-Moreno, Peter Button, Myung-Ju Ahn, Tony Mok
IMPORTANCE: Continuing molecularly targeted treatment beyond disease progression in non-small-cell lung cancer (NSCLC) has appeared promising in retrospective analyses, highlighting the challenge to identify whether progression is the optimal time to switch treatment. OBJECTIVE: To study the efficacy of first-line erlotinib therapy in patients with NSCLC with activating EGFR mutations and postprogression erlotinib therapy. DESIGN, SETTING, AND PARTICIPANTS: ASPIRATION (Asian Pacific trial of Tarceva as first-line in EGFR mutation) was a phase 2, open-label, single-arm study conducted from 2011 to 2012 in 23 centers in Hong Kong, Korea, Taiwan, and Thailand of adults with stage IV, EGFR mutation-positive NSCLC, with ECOG performance status 0 to 2...
March 2016: JAMA Oncology
Katharina Schremser, Wolf H Rogowski, Sigrid Adler-Reichel, Amanda L H Tufman, Rudolf M Huber, Björn Stollenwerk
BACKGROUND: Lung cancer is among the top causes of cancer-related deaths. Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors can increase progression-free survival compared with standard chemotherapy in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). OBJECTIVE: The aim of the study was to evaluate the cost-effectiveness of EGFR mutation analysis and first-line therapy with erlotinib for mutation-positive patients compared with non-individualized standard chemotherapy from the perspective of German statutory health insurance...
November 2015: PharmacoEconomics
Niina Laurila, Jussi P Koivunen
Acquired resistance to EGFR TKIs is the most important limiting factor for treatment efficiency in EGFR-mutant NSCLC. Although the continuation of EGFR TKI beyond disease progression in combination with chemotherapy is often suggested as a strategy for treating acquired resistance, the optimal treatment sequence for EGFR TKI and chemotherapy is unknown. In the current work, NSCLC cell lines PC9ER, H1975 and HCC827GR, representing the acquired TKI resistance genotypes (T790M, cMET), were exposed to a chemotherapeutic agent, cisplatin or paclitaxel, in combination with EGFR TKIs (erlotinib, WZ4002) in vitro and analysed for cytotoxicity and apoptotic response...
July 2015: Medical Oncology
Olivier Carpentier, Lucia Selvaggi, Jérémie Jégu, Ashok Purohit, Nathalie Prim, Michel Velten, Elisabeth Quoix
UNLABELLED: Extrapolation of clinical trials results to the general population is always challenging. We analysed 1047 patients diagnosed with an advanced stage disease between 1998 and 2005 in a french administrative department and found a good spread of modern chemotherapy since 1998 and targeted therapy since 2002. Moreover, the outcomes in patients treated according to guidelines are very proximal from those obtained in clinical trials. BACKGROUND: Management of metastatic non-small-cell lung cancer has considerably evolved during the past 2 decades...
November 2015: Clinical Lung Cancer
Matteo Santoni, Alessandro Conti, Kalliopi Andrikou, Alessandro Bittoni, Andrea Lanese, Mirco Pistelli, Francesco Pantano, Bruno Vincenzi, Grazia Armento, Francesco Massari, Giuseppe Tonini, Stefano Cascinu, Daniele Santini
BACKGROUND: Pruritus has been described with targeted therapies in cancer patients. We performed an up-to-date meta-analysis to determine the incidence and RR in patients with cancer treated with these agents. METHODS: PubMed databases were searched for articles published till October 2014. Eligible studies were selected according to PRISMA statement. Summary incidence, RR, and 95% CIs were calculated using random-effects or fixed-effects models based on the heterogeneity of selected studies...
November 2015: Critical Reviews in Oncology/hematology
Jack P Wang, Chen-Yi Wu, Yi-Cheng Yeh, Yi-Ming Shyr, Ying-Ying Wu, Chen-Yu Kuo, Yi-Ping Hung, Ming-Huang Chen, Wei-Ping Lee, Jiing-Chyuan Luo, Yee Chao, Chung-Pin Li
OBJECTIVE: To analyze the efficacy of gemcitabine with or without erlotinib for pancreatic cancer, and to determine the predictive role of epidermal growth factor receptor (EGFR) and KRAS mutations in these patients. METHODS: This was a single-center, randomized, open-label, prospective trial. Eighty-eight chemotherapy-naïve metastatic pancreatic cancer patients were randomized for treatment with gemcitabine or gemcitabine plus erlotinib. EGFR and KRAS mutations were analyzed, respectively...
July 20, 2015: Oncotarget
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"